Astellas Pharma Inc.
Astellas Pharma Inc. (ALPMF) Financial Performance & Income Statement Overview
Explore the financials of Astellas Pharma Inc. (ALPMF), including yearly and quarterly data on income, cash flow, and balance sheets.
Astellas Pharma Inc. (ALPMF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Astellas Pharma Inc. ALPMF financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $459.29B | $517.41B | $462.50B | $473.12B |
| Cost of Revenue | $109.42B | $98.52B | $116.93B | $91.14B |
| Gross Profit | $349.88B | $418.88B | $345.57B | $381.99B |
| Gross Profit Ratio | $0.76 | $0.81 | $0.75 | $0.81 |
| R&D Expenses | $76.23B | $79.09B | $85.51B | $86.82B |
| SG&A Expenses | $211.32B | $225.31B | $199.53B | $206.88B |
| Operating Expenses | $287.55B | $535.08B | $285.04B | $331.33B |
| Total Costs & Expenses | $396.96B | $633.60B | $399.33B | $422.47B |
| Interest Income | $940.00M | $2.06B | $541.00M | $4.33B |
| Interest Expense | $3.91B | $4.23B | $5.05B | $4.50B |
| Depreciation & Amortization | $47.68B | $51.16B | $50.02B | $50.27B |
| EBITDA | $111.78B | $126.06B | $94.09B | $103.33B |
| EBITDA Ratio | $0.24 | $0.24 | $0.20 | $0.22 |
| Operating Income | $62.33B | -$116.19B | $60.53B | $53.32B |
| Operating Income Ratio | $0.14 | -$0.22 | $0.13 | $0.11 |
| Other Income/Expenses (Net) | -$2.14B | -$2.17B | -$21.50B | -$2.82B |
| Income Before Tax | $60.19B | -$118.36B | $39.03B | $50.49B |
| Income Before Tax Ratio | $0.13 | -$0.23 | $0.08 | $0.11 |
| Income Tax Expense | -$14.34B | -$20.70B | $2.64B | $12.89B |
| Net Income | $74.90B | -$97.66B | $35.91B | $37.60B |
| Net Income Ratio | $0.16 | -$0.19 | $0.08 | $0.08 |
| EPS | $41.84 | -$54.57 | $19.94 | $21.00 |
| Diluted EPS | $41.84 | -$54.57 | $19.94 | $20.94 |
| Weighted Avg Shares Outstanding | $1.79B | $1.79B | $1.80B | $1.80B |
| Weighted Avg Shares Outstanding (Diluted) | $1.79B | $1.79B | $1.80B | $1.80B |
Over the last four quarters, Astellas Pharma Inc.'s revenue moved from $473.12B in Q1 2024 to $459.29B in Q4 2024. Operating income in Q4 2024 was $62.33B, with a strong operating margin of 14%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Astellas Pharma Inc. remained robust at $111.78B, reflecting operational efficiency. Net income rose to $74.90B, with an EPS of $41.84. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan